As Entresto Sales Soar, Novartis Braces For Generics Battle

Swiss Major Is Banking On China To Drive Growth

Novartis CEO Vas Narasimhan has told Scrip that the company is “aggressively defending each group of patents” on its cardiovascular blockbuster which topped the $900m sales mark in the fourth quarter.

Human heart. 3d illustration.
• Source: Archive

Novartis AG has heralded another strong quarter of sales growth for Entresto but is setting up its defences to keep the threat of generic competition at bay, while planning for further growth in the lucrative China market.

Fourth-quarter sales of Entresto (sacubitril/valsartan) shot up by 24% to $924m, which the company said was due to sustained strong...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Cardiovascular

More from Therapeutic Category